These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12799288)

  • 41. Gene Therapy for Hemoglobinopathies.
    Lidonnici MR; Scaramuzza S; Ferrari G
    Hum Gene Ther; 2023 Sep; 34(17-18):793-807. PubMed ID: 37675899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetic correction of sickle cell anemia and beta-thalassemia: progress and new perspective.
    Perumbeti A; Malik P
    ScientificWorldJournal; 2010 Apr; 10():644-54. PubMed ID: 20419277
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical Features of β-Thalassemia and Sickle Cell Disease.
    McGann PT; Nero AC; Ware RE
    Adv Exp Med Biol; 2017; 1013():1-26. PubMed ID: 29127675
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease.
    Sadelain M; Rivella S; Lisowski L; Samakoglu S; Rivière I
    Best Pract Res Clin Haematol; 2004 Sep; 17(3):517-34. PubMed ID: 15498721
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hemoglobin gene therapy for β-thalassemia.
    Bank A
    Hematol Oncol Clin North Am; 2010 Dec; 24(6):1187-201. PubMed ID: 21075288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells.
    Imren S; Payen E; Westerman KA; Pawliuk R; Fabry ME; Eaves CJ; Cavilla B; Wadsworth LD; Beuzard Y; Bouhassira EE; Russell R; London IM; Nagel RL; Leboulch P; Humphries RK
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14380-5. PubMed ID: 12391330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Progress toward the genetic treatment of the beta-thalassemias.
    Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
    Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infusion of autologous retrodifferentiated stem cells into patients with beta-thalassemia.
    Abuljadayel IS; Quereshi H; Ahsan T; Rizvi S; Ahmed T; Khan SM; Akhtar J; Dhoot G
    ScientificWorldJournal; 2006 Oct; 6():1278-97. PubMed ID: 17041717
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion.
    Negre O; Fusil F; Colomb C; Roth S; Gillet-Legrand B; Henri A; Beuzard Y; Bushman F; Leboulch P; Payen E
    Blood; 2011 May; 117(20):5321-31. PubMed ID: 21436071
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene transfer. A potential approach to gene therapy for sickle cell disease.
    Bank A; Markowitz D; Lerner N
    Ann N Y Acad Sci; 1989; 565():37-43. PubMed ID: 2672970
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene Therapy for β-Hemoglobinopathies.
    Cavazzana M; Antoniani C; Miccio A
    Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Major challenges for gene therapy of thalassemia and sickle cell disease.
    Papanikolaou E; Anagnou NP
    Curr Gene Ther; 2010 Oct; 10(5):404-12. PubMed ID: 20712578
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice.
    Lisowski L; Sadelain M
    Blood; 2007 Dec; 110(13):4175-8. PubMed ID: 17921347
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene therapy and gene editing strategies for hemoglobinopathies.
    Lidonnici MR; Ferrari G
    Blood Cells Mol Dis; 2018 May; 70():87-101. PubMed ID: 29336892
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Towards more successful gene therapy clinical trials for β-thalassemia.
    Drakopoulou E; Papanikolaou E; Georgomanoli M; Anagnou NP
    Curr Mol Med; 2013 Sep; 13(8):1314-30. PubMed ID: 23865429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene replacement therapy for sickle cell disease and other blood disorders.
    Townes TM
    Hematology Am Soc Hematol Educ Program; 2008; ():193-6. PubMed ID: 19074080
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Engineered U7 snRNA mediates sustained splicing correction in erythroid cells from β-thalassemia/HbE patients.
    Preedagasamzin S; Nualkaew T; Pongrujikorn T; Jinawath N; Kole R; Fucharoen S; Jearawiriyapaisarn N; Svasti S
    Biochem Biophys Res Commun; 2018 Apr; 499(1):86-92. PubMed ID: 29550480
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of optimal expression cassette in retrovirus vector for beta-thalassemia gene therapy.
    Dong WJ; Li B; Liu DP; Zu ZX; Li J; Hao DL; Liu G; Guo ZC; Liang CC
    Mol Biotechnol; 2003 Jun; 24(2):127-40. PubMed ID: 12746554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease.
    Cui S; Engel JD
    Adv Exp Med Biol; 2017; 1013():177-202. PubMed ID: 29127681
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A promising genetic approach to the treatment of beta-thalassemia.
    May C; Sadelain M
    Trends Cardiovasc Med; 2001 Oct; 11(7):276-80. PubMed ID: 11709281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.